Novel Therapeutics for Immunological Diseases
Developing safer, more durable treatments to improve the lives of patients
More

AbGn-168H Neihulizumab
100
100
100
0
0
Phase II
Phase II Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.
100
100
100
0
0
Phase II
Phase II Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with leiolizumab.
100
50
0
0
0
Phase I
Phase I Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing
100
50
0
0
0
Phase I
Phase I Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
50
0
0
0
0
Phase I
Phase I Renal Transplantation Non-Human Primate preclinical studies ongoing.
AbGn-268 Leiolizumab
80
0
0
0
0
Preclinical
Preclinical Potency improved version of AbGn-168H for Chronic Inflammatory Disease
Discover, Develop and Deliver
Innovative Therapies That Make an Impact
2F, No. 36, Lane. 358, Juikuang Road
Neihu, Taipei, Taiwan 11492
Tel: (886)-2-2627-2707
E-mail: info@altrubio.com
555 Twin Dolphin Drive, Suite #310,
Redwood City, CA94065 U.S.A.
Tel: (650)453-3462
E-mail: info@altrubio.com
Kingsfordweg 103, 1043 GP Amsterdam
The Netherlands
Tel: +31 (0)88-1009333
E-mail: abgcoop@abgenomics.nl